The mouse dorsal skinfold chamber as a model for the study of thrombolysis by intravital microscopy

Summary

Although intravital microscopy models of thrombosis in mice have contributed to dissect the mechanisms of thrombus formation and stability, they have not been well adapted to study long-term evolution of occlusive thrombi. Here, we assessed the suitability of the dorsal skinfold chamber (DSC) for the study of thrombolysis and testing of thrombolytic agents by intravital microscopy. We show that induction of FeCl₃-induced occlusive thrombosis is achievable in microvessels of DSCs, and that thrombi formed in DSCs can be visualised by intravital microscopy using brightfield transmitted light, or fluorescent staining of thrombus components such as fibrinogen, platelets, leukocytes, and von Willebrand factor. Direct application of control saline or recombinant tissue-plasminogen activator (rtPA) to FeCl₃-produced thrombi in DSCs did not affect thrombus size or induce recanalisation. However, in the presence of hirudin, rtPA treatment caused a rapid dose-dependent lysis of occlusive thrombi, resulting in recanalisation within 1 hour after treatment. Skin haemorrhage originating from vessels located inside and outside the FeCl₃-injured area was also observed in DSCs of rtPA-treated mice. We further show that rtPA-induced thrombolysis was enhanced in plasminogen activator inhibitor-1-deficient (PAI-1−/−) mice, and dropped considerably as the time between occlusion and treatment application increased. Together, our results show that by allowing visualization and measurement of thrombus lysis and potential bleeding complications of thrombolytic treatments, the DSC provides a model for studying endogenous fibrinolysis and for first-line screening of thrombolytic agents. Furthermore, using this system, we found that thrombin and clot aging impair the thrombolytic action of rtPA towards FeCl₃-produced thrombi.

Keywords

Dorsal skinfold chamber - intravital microscopy - thrombolysis - thrombosis - tPA

Y.B. and L.L. contributed equally to this study.

• References

• 1 Bizzozero G. Ueber einen neuen Formbestandteil des Blutes und dessen Rolle bei der Thrombose und Blutgerinnung. Archiv für pathologische Anatomie und Physiologie und für klinische Medicin 1882; 90: 261-332.
• 2 Chauhan AK, Motto DG, Lamb CB. et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med 2006; 203: 767-76.
• 3 Boulaftali Y, Adam F, Venisse L. et al. Anticoagulant and antithrombotic properties of platelet protease nexin-1. Blood 2010; 115: 97-106.
• 4 Cambien B, Bergmeier W, Saffaripour S. et al. Antithrombotic activity of TNF-alpha. J Clin Invest 2003; 112: 1589-1596.
• 5 Diener JL, Daniel Lagasse HA, Duerschmied D. et al. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J Thromb Haemost 2009; 07: 1155-1162.
• 6 Ni H, Denis CV, Subbarao S. et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000; 106: 385-392.
• 7 Ni H, Papalia JM, Degen JL. et al. Control of thrombus embolization and fibronectin internalization by integrin alpha IIb beta 3 engagement of the fibrinogen gamma chain. Blood 2003; 102: 3609-3614.
• 8 Ni H, Ramakrishnan V, Ruggeri ZM. et al. Increased thrombogenesis and embolus formation in mice lacking glycoprotein V. Blood 2001; 98: 368-373.
• 9 Wang YX, da Cunha V, Vincelette J. et al. A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Thromb Haemost 2007; 97: 54-61.
• 10 Wadanoli M, Sako D, Shaw GD. et al. The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time. Thromb Haemost 2007; 98: 397-405.
• 11 Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 1999; 99: 3050-3055.
• 12 Orbe J, Barrenetxe J, Rodriguez JA. et al. Matrix Metalloproteinase-10 Effectively Reduces Infarct Size in Experimental Stroke by Enhancing Fibrinolysis via a Thrombin-Activatable Fibrinolysis Inhibitor-Mediated Mechanism. Circulation 2011; 124: 2909-2919.
• 13 Roussel BD, Mysiorek C, Rouhiainen A. et al. HMGB-1 promotes fibrinolysis and reduces neurotoxicity mediated by tissue plasminogen activator. J Cell Sci 2011; 124: 2070-2076.
• 14 Koehl GE, Gaumann A, Geissler EK. Intravital microscopy of tumor angiogenesis and regression in the dorsal skin fold chamber: mechanistic insights and preclinical testing of therapeutic strategies. Clin Exp Metastasis 2009; 26: 329-344.
• 15 Harder Y, Amon M, Erni D. et al. Evolution of ischemic tissue injury in a random pattern flap: a new mouse model using intravital microscopy. J Surg Res 2004; 121: 197-205.
• 16 Nolte D, Menger MD, Messmer K. Microcirculatory models of ischaemia-reperfusion in skin and striated muscle. Int J Microcirc Clin Exp 1995; 15 (Suppl. 01) 9-16.
• 17 Lehr HA, Leunig M, Menger MD. et al. Dorsal skinfold chamber technique for intravital microscopy in nude mice. Am J Pathol 1993; 143: 1055-1062.
• 18 Eckly A, Hechler B, Freund M. et al. Mechanisms underlying FeCl₃-induced arterial thrombosis. J Thromb Haemost 2011; 09: 779-789.
• 19 Broersma RJ, Kutcher LW, Heminger E F. The effect of thrombin inhibit ion in a rat arterial thrombosis model. Thromb Res 1991; 64: 405-412.
• 20 Kuijpers MJ, Munnix IC, Cosemans JM. et al. Key role of platelet procoagulant activity in tissue factor-and collagen-dependent thrombus formation in arterioles and venules in vivo differential sensitivity to thrombin inhibition. Microcirculation 2008; 15: 269-282.
• 21 Wang X, Cheng Q, Xu L. et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost 2005; 03: 695-702.
• 22 Day SM, Reeve JL, Pedersen B. et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood 2005; 105: 192-198.
• 23 Grines CL, Serruys P, O'Neill WW. Fibrinolytic therapy: is it a treatment of the past?. Circulation 2003; 107: 2538-2542.
• 24 Kilic E, Hermann DM, Hossmann KA. Recombinant tissue-plasminogen activator-induced thrombolysis after cerebral thromboembolism in mice. Acta Neuropathol 2000; 99: 219-222.
• 25 Orset C, Macrez R, Young AR. et al. Mouse model of in situ thromboembolic stroke and reperfusion. Stroke 2007; 38: 2771-2778.
• 26 Jang IK, Gold HK, Ziskind AA. et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. A possible explanation for resistance to coronary thrombolysis. Circulation 1989; 79: 920-928.
• 27 Mazighi M, Serfaty JM, Labreuche J. et al. Comparison of intravenous alteplase with a combined intravenous-endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study. Lancet Neurol 2009; 08: 802-809.
• 28 Ouriel K. Current status of thrombolysis for peripheral arterial occlusive disease. Ann Vasc Surg 2002; 16: 797-804.
• 29 Kim HS, Preece SR, Black JH. et al. Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients. J Vasc Surg 2008; 47: 388-394.
• 30 Mewissen MW, Seabrook GR, Meissner MH. et al. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology 1999; 211: 39-49.
• 31 Kuo WT, van den Bosch MA, Hofmann LV. et al. Catheter-directed embolectomy, fragmentation, and thrombolysis for the treatment of massive pulmonary embolism after failure of systemic thrombolysis. Chest 2008; 134: 250-254.
• 32 Kuo WT, Gould MK, Louie JD. et al. Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol 2009; 20: 1431-1440.
• 33 Korninger C, Collen D. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro. Thromb Haemost 1981; 46: 561-565.
• 34 Lijnen HR, van Hoef B, Beelen V. et al. Characterization of the murine plasma fibrinolytic system. Eur J Biochem 1994; 224: 863-871.
• 35 Lapergue B, Moreno JA, Dang BQ. et al. Protective effect of high-density lipoprotein-based therapy in a model of embolic stroke. Stroke 2010; 41: 1536-1542.
• 36 Atochin DN, Murciano JC, Gursoy-Ozdemir Y. et al. Mouse model of microembolic stroke and reperfusion. Stroke 2004; 35: 2177-2182.
• 37 Dubois C, Panicot-Dubois L, Merrill-Skoloff G. et al. Glycoprotein VI-dependent and -independent pathways of thrombus formation in vivo. Blood 2006; 107: 3902-3906.
• 38 Boulaftali Y, Ho-Tin-Noe B, Pena A. et al. Platelet protease nexin-1, a serpin that strongly influences fibrinolysis and thrombolysis. Circulation 2011; 123: 1326-1334.
• 39 Fay WP, Eitzman DT, Shapiro AD. et al. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms. Blood 1994; 83: 351-356.
• 40 Francis CW, Marder VJ. Rapid formation of large molecular weight alphapolymers in cross-linked fibrin induced by high factor XIII concentrations. Role of platelet factor XIII. J Clin Invest 1987; 80: 1459-1465.
• 41 McDonagh J, McDonagh Jr. RP, Delage JM. et al. Factor XIII in human plasma and platelets. J Clin Invest 1969; 48: 940-946.
• 42 Kunitada S, FitzGerald GA, Fitzgerald DJ. Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. Blood 1992; 79: 1420-1427.
• 43 Zaidat OO, Suarez JI, Sunshine JL. et al. Thrombolytic therapy of acute ischemic stroke: correlation of angiographic recanalization with clinical outcome. AJNR Am J Neuroradiol 2005; 26: 880-884.
• 44 Lees KR, Bluhmki E, von Kummer R. et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-1703.
• 45 Westerhout CM, Bonnefoy E, Welsh RC. et al. The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: a pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST. Am Heart J 2011; 161: 283-290.
• 46 Steg PG, Bonnefoy E, Chabaud S. et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003; 108: 2851-2856.
• 47 Kennedy JW. Optimal management of acute myocardial infarction requires early and complete reperfusion. Circulation 1995; 91: 1905-1907.